SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells by Ohanna, M. (M) et al.
Oncotarget2085www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 8
SIRT1 promotes proliferation and inhibits the senescence-like 
phenotype in human melanoma cells
Mickaël Ohanna 1,2, Caroline Bonet1,2, Karine Bille1,2, Maryline Allegra1,2, Irwin 
Davidson3, Philippe Bahadoran2,4, Jean-Philippe Lacour2,4, Robert Ballotti1,2 and 
Corine Bertolotto1,2.
1, INSERM, U1065 (équipe 1), Equipe labélisée Ligue Contre le Cancer, C3M, Nice, France.
2, Université de Nice Sophia-Antipolis, UFR Médecine, Nice, France.
3, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS, INSERM, Université de Strasbourg, Illkirch, France.
4, Centre Hospitalier Universitaire, Service de Dermatologie, Nice, France
Correspondence to: Corine Bertolotto, email: bertolot@unice.fr
Keywords: melanoma, MITF, SIRT1, PLX4032, treatment
Received:  February 7, 2014 Accepted:February 18, 2014 Published: February 19, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
SIRT1 operates as both a tumor suppressor and oncogenic factor depending on 
the cell context. Whether SIRT1 plays a role in melanoma biology remained poorly 
elucidated. Here, we demonstrate that SIRT1 is a critical regulator of melanoma 
cell proliferation. SIRT1 suppression by genetic or pharmacological approaches 
induces cell cycle arrest and a senescence-like phenotype. Gain and loss of function 
experiments show that M-MITF regulates SIRT1 expression, thereby revealing 
a melanocyte-specific control of SIRT1. SIRT1 over-expression relieves the 
senescence-like phenotype and the proliferation arrest caused by MITF suppression, 
demonstrating that SIRT1 is an effector of MITF-induced proliferation in melanoma 
cells. Interestingly, SIRT1 level and activity are enhanced in the PLX4032-resistant 
BRAFV600E-mutated melanoma cells compared with their sensitive counterpart. SIRT1 
inhibition decreases melanoma cell growth and rescues the sensibility to PLX4032 of 
PLX4032-resistant BRAFV600E-mutated melanoma cells. In conclusion, we provide the 
first evidence that inhibition of SIRT1 warrants consideration as an anti-melanoma 
therapeutic option. 
INTRODUCTION
The class III histone deacetylases known as sirtuins 
has been associated with longer lifespan in yeast and 
worms. The mammalian ortholog SIRT1 has emerged 
as an important regulator of cancer and ageing. SIRT1 
controls gene expression, cell cycle regulation, apoptosis, 
DNA repair, metabolism and senescence. The role of 
SIRT1 is however somewhat puzzling, acting both as a 
tumor suppressor or tumor promoter. It is thought that the 
precise role of SIRT1 may depend on the specific cell or 
tumor type and the presence or absence of p53 [1]. This 
tissue-specificity role might also involve, if any, tissue-
specific regulation. A better understanding of the role 
of SIRT1 in specific tissues will provide the molecular 
basis for development of novel anti-aging and anti-cancer 
therapeutic targets. Up to now, the role of SIRT1 in 
melanoma is unknown.
Melanoma is a very aggressive neoplasm, well-
known for its resistance to apoptotic stimuli. Apoptotic 
resistance represents an important cause, which limits 
the efficacy of the anti-melanoma therapies developed 
so far. Senescence is another important cellular failsafe 
mechanism, which is characterized by a state of stable cell 
cycle arrest. Senescence arises ordinarily in normal cells 
in response to telomere erosion or to oncogenic stresses. 
Although most cancer cells have conceivably bypassed 
OIS, several lines of evidence recently indicated that 
cellular senescence remains latently functional and can be 
reactivated in cancer cells, including melanoma cells. 
Microphthalmia-associated transcription factor 
(M-MITF) is a melanocyte lineage-specific transcription 
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factor of the c-myc supergene family. Its role in 
melanocyte physiopathology is complex. C. Goding 
and co-workers proposed that expression level, post-
translational modification and co-factors, create a bar 
code-like situation which channels MITF towards a 
specific subset of target genes and determines MITF 
activity according to the cell context [2, 3]. Hence, MITF 
plays a critical role in melanocyte development [4] and 
functioning [5, 6] but it is also considered a bona fide 
melanoma oncogene. Indeed, genomic amplification 
of MITF associated with a decreased five-year survival 
[7] and germline mutation that predisposes carriers to 
melanoma [8-10] were reported. Understanding the 
molecular mechanisms underlying the role of MITF 
according to the melanocyte context is critically required.
Here, we observe an increased SIRT1 activity in 
human melanoma cells compared with normal human 
melanocytes. We demonstrate that SIRT1 suppression 
induces a senescence-like phenotype and its associated 
cell proliferation arrest. Based on the observation that 
SIRT1 suppression mimics some of the MITF knock-
down effect, we investigated the epistatic relationship 
between MITF and SIRT1. Our results reveal that MITF 
controls SIRT1 expression at the transcriptional level. 
Moreover, SIRT1 overexpression relieves the senescence-
like phenotype and the proliferation arrest caused by 
MITF knock-down, thereby demonstrating that SIRT1 is 
an effector of MITF-induced proliferation in melanoma 
cells. Our results reveal that SIRT1 activity is higher in 
PLX4032-resistant BRAFV600E-mutated melanoma cells 
compared with their sensitive counterpart. Furthermore, 
SIRT1 level and activity are dramatically inhibited in 
BRAFV600E-mutated melanoma cells sensitive to PLX4032, 
whereas they remain elevated in their resistant counterpart. 
Most importantly, SIRT1 inhibition rescues the sensitivity 
to PLX4032 of the resistant BRAFV600E-mutated melanoma 
cells.
RESULTS
SIRT1 activity is elevated in melanoma cells
SIRT1 and AMPK are two energy metabolic 
sensors, and metabolism alteration is a crucial hallmark of 
cancer [11]. Whereas AMPK has been recently implicated 
in melanoma disease [12, 13], the role of SIRT1 has never 
been investigated. To determine the role of SIRT1 we first 
assessed SIRT1 activity in melanoma cell lines and in 
cells freshly isolated from human biopsies, and in normal 
human melanocytes. To this aim, we assessed the degree 
of deacetylation of a substrate which represents a peptide 
containing amino acids 379-382 of human p53 (Arg-His-
Lys-Lys[Ac]), an established target of SIRT1 activity. 
The results showed an increased deacetylation of the p53 
peptide in several melanoma cells of different genetic 
backgrounds compared with three different cultures of 
normal human melanocytes (Figure 1).
These results indicate that SIRT1 activity is 
enhanced during melanocyte transformation. 
SIRT1 suppression promotes a senescence-like 
phenotype and its associated cell proliferation 
arrest 
Based on these observations, we investigated the 
impact of SIRT1 suppression in 501mel melanoma cells 
with specific siRNA, which triggered an efficient SIRT1 
inhibition (Figure 2A). SIRT1 knock-down was associated 
with an increase in the level of the cell cycle inhibitors 
p27KIP1, p15 and the tumor suppressor p53 and with a 
decreased expression of HDMX the p53 regulator (Figures 
2A-B). Accordingly, SIRT1 suppressed melanoma cells 
displayed an hypophosphorylation of the retinoblastoma 
protein (Figures 2A-B), and a G0/G1 cell cycle arrest 
(Figure 2C). Accordingly, SIRT1-suppressed 501mel 
cells stopped proliferating after 72 hrs compared with 
cells transfected with a control siRNA (Figure 2D). The 
proliferation arrest also translated into a reduced ability 
to form anchorage-dependent and independent colonies 
(Figures 2G-H). Reduction in cell proliferation and/or 
colony formation was observed in several melanoma cell 
lines and in cells freshly isolated from human biopsies 
harboring the BRAFV600E mutation (501mel, A375, WM9 
and C.09-02) or the NRASQ61K/R mutation (HMVII and 
C.12-38) or in cells wild-type for BRAF and NRAS 
(SBCL2, Mel-ST) (Figures 2D-H, S1A-B). Collectively, 
these observations indicate that SIRT1 silencing promotes 
a cell cycle arrest in melanoma cells of different genetic 
background. To rule out the possibility of non-specific 
Figure 1: SIRT1 activity is elevated in melanoma cells. 
SIRT1 activity was determined in melanoma cells of different 
genetic background and in normal melanocytes using an in 
vitro deacetylation assay. Relative SIRT1 activity is expressed 
as arbitrary fluorescence units (AFU). Values are expressed as 
box-and-whisker plots (n=3).
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effect, we used a second siRNA (siSIRT1#2), both 
siRNA suppressed SIRT1, elevated the level of cell cycle 
inhibitors (Figure 2A-B) and reduced cell proliferation 
(Figure S1A) to similar extent.
We next determined the underlying mechanisms 
by which SIRT1 suppression caused cessation of cell 
proliferation in melanoma cells. SIRT1 silencing was 
reported to induce senescence or apoptosis depending 
on the cell type [14]. Melanoma cells from the above 
experiments showed no morphological sign of cell death, 
prompting us to argue that SIRT1 knock-down would 
trigger a senescence-like phenotype in melanoma cells. 
Compared with control siRNA, the two different 
SIRT1 siRNA promoted a 70-80% increase in the 
senescence-associated β-galactosidase (SA-βGal) 
biomarker detected either by histochemical staining 
(Figure 3A) or FACS analysis (Figure 3B). In addition, 
an increase in cell size (Figure 3C) and in cell granularity 
(Figure 3D) were observed. Immunofluorescence studies 
showed that SIRT1-suppressed cells engaged the DNA 
damage response, a signaling pathway commonly 
associated with senescence, as illustrated by an induction 
in γH2AX and the detection of 53BP1 foci (Figures 
2A and 3E). Likewise, SIRT1 suppression induced 
senescence-like phenotypes in different melanoma 
cells lines (Figure S1C). Senescence in melanoma cells 
Figure 2: SIRT1 suppression triggers growth arrest. 
(A-B) Western blot analysis of 501mel cells transfected with a 
control siRNA (siC) or two SIRT1 specific siRNAs (siSIRT1 
and siSIRT1#2) for 96 hrs. (C) The cell cycle was analysed by 
FACS in 501mel cells transfected with control or SIRT1 siRNA 
for 96 hrs. Shown are the average values and standard deviations 
of three independent experiments. p-values of <0,01 (**) and 
of <0,001 (***) were considered statistically significant. (D-F) 
501mel, SBCL2 and A375 human melanoma cells were plated 
in 6-well dishes, transfected with control (red line), or SIRT1 
(blue line) siRNA and counted in triplicates from days 2 to 4. (G) 
Colony formation of 501mel cells transfected with control, or 
SIRT1 siRNA was assessed after 14 days. Representative images 
of colonies formed are shown. (H) Same as (G) but examined for 
anchorage-independent growth (polyHema). Colony formation 
was assessed after 21 days. Representative images of colonies 
formed are shown.
Figure 3: SIRT1 suppresses senescence. (A) 501mel cells 
were transfected with control (siC) or two SIRT1 siRNA (siSIRT1 
and siSIRT1#2) for 96 hrs and were stained for SA-βGal activity. 
The percentage of means and standard deviations (+SD) of 
β-Galactosidase positive cells were derived from counting 100 
cells in duplicate plates. Enlargement of the cell is shown. (B) 
Same as (A) but examined for C12FDG staining. Mean values + 
SD. (C) The relative size (forward scatter) and (D) relative cell 
granularity (side scatter) of control or SIRT1-suppressed 501mel 
cells were analyzed by flow cytometry. Shown are the results of 
two independent experiments. (E) Immunofluorescence analysis 
with antibody to SIRT1 and 53BP1 of cells transfected with 
control (siC) or SIRT1 siRNA for 96 hrs. (F) NF-kB luciferase 
activity of 501mel cells transfected with control (siC) or SIRT1 
siRNA for 96 hrs. (G) CCL2 mRNA level analysed by QRT-PCR 
in 501mel cells transfected with control or SIRT1 siRNA. (H) 
SIRT1 level in a subset of nevi and primary melanomas. The 
dataset was previously published under GSE46517.
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is associated with production of a NF-κB-dependent 
secretome, which contains the chemokine CCL2 [15]. 
We used a vector containing NF-κB response elements 
that drives downstream transcription of the luciferase 
reporter gene. The increased luciferase activity in 
response to SIRT1 siRNA reflected an activation of the 
NF-κB signaling pathway (Figure 3F). Production of the 
senescence-associated secretory phenotype revealed by 
increased CCL2 mRNA expression was also observed 
(Figure 3G). Our findings were further substantiated 
using pharmacological inhibitors of SIRT1 (sirtinol, EX-
527), which enhanced histone H3 acetylation on lysine 
9 (H3K9Ac), another well-known SIRT1 substrate, and 
engendered similar level of SA-βGal stained cells (Figures 
S2B-D). We next sought to determine the relevance 
of SIRT1 in vivo. We compared the SIRT1 expression 
profile in a previously published dataset [16]. The analysis 
disclosed a significant lower expression of SIRT1 in nevi, 
benign melanocytic lesions compared with melanomas 
(Figure 3H). Collectively, reduction in SIRT1 level is 
associated with a decrease in cell proliferation and with 
traits of cellular senescence.
MITF regulates SIRT1 deacetylase activity
Interestingly, we noticed that the senescence effects 
triggered by SIRT1 suppression in 501mel cells partly 
overlaped those of MITF knock-down. We therefore 
asked whether MITF could affect SIRT1 activity. We 
observed that MITF suppression by siRNA significantly 
reduced (about 50%) the level of deacetylated p53 peptide, 
indicating that MITF suppression reduced the activity 
of SIRT1. As a positive control, we measured SIRT1 
activity in SIRT1-suppressed cells by two different SIRT1 
siRNA that led to an almost complete inhibition of p53 
peptide deacetylation (Figure 4A). MITF suppression also 
increased histone H3 acetylation on lysine 9 as judged 
by western blotting (Figure 4B) or immunofluorescence 
(Figure 4C) experiments. In aggregates, the results 
demonstrate that MITF regulates the activity of SIRT1, 
which is accompanied by a change in the acetylation status 
of its downstream target such as p53 and histone H3. 
MITF controls the level of SIRT1 
Having shown that MITF suppression impaired 
SIRT1 activity, we investigated the impact of MITF 
on SIRT1 expression. In support of this idea, previous 
transcriptomic analysis suggested that, among members 
of the sirtuin gene family, only SIRT1 was decreased in 
MITF silenced cells (Figure S3A). QRT-PCR experiments 
in two melanoma cell lines (501mel, WM9) and in cells 
freshly isolated from a human biopsy (C-09.02) showed, 
as expected, that MITF suppression by siRNA, compared 
with control cells, caused a decreased mRNA expression 
of two of its target genes, MLANA and CDK2 [17] and 
an increased mRNA expression of CCL2, as previously 
reported (Figures 5A and S3B-C) [15]. mRNA expression 
of SIRT1 was decreased in MITF-silenced cells compared 
with control cells and was associated with a concomitant 
change in genes involved in mitochondrial biogenesis, 
such as PGC1α and one of its target gene NRF1 (Figure 
5B).
Western blot analysis confirmed that MITF 
knock-down with two different siRNA correlated with 
a substantial reduction in SIRT1 level (Figure 5C). 
Likewise, immunofluorescences showed that SIRT1 
mainly localized to the nucleus in melanoma cells and that 
SIRT1 reduction paralleled that of MITF (Figure S3D). 
We next assessed whether reduction of MITF by hypoxia, 
a situation commonly found in tumors, also triggered a 
change in SIRT1 level. Kinetics of hypoxia, as judged 
by the stabilization of HIF1α, reduced MITF expression 
[18] and one of its target gene CDK2 [17] as previously 
reported respectively, which was also accompanied by a 
decreased expression of SIRT1 (Figure 5D). Conversely, 
forced expression of MITF caused elevation of SIRT1 
expression (Figure 5E). Moreover, in condition of MITF 
regulation via activation of the cAMP-pathway [5], the 
known MITF target RAB27a [19] and SIRT1 expression 
were enhanced as a function of time (Figure 5F). These 
results strongly suggested the existence of an epistatic 
relationship between MITF and SIRT1. We therefore 
searched in our previously published MITF-ChIP-seq 
Figure 4: MITF regulates the activity of SIRT1. (A) 
In vitro deacetylation assay in cells transfected with control, 
MITF or two different SIRT1 siRNA. Activity is expressed 
as the percentage of activity with respect to the control. AFU, 
Arbitrary fluorescence units. Error bar represents the SEM of 
triplicate experiments. (B) Western blot analysis of 501mel cells 
transfected with control (siC), MITF (siMi) or SIRT1 siRNA. 
(C) Same as (B) but examined by immunofluorescence with 
anti-MITF and anti-histone H3K9 acetyl antibody. 
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data for genomic sites bound by MITF in the SIRT1 locus 
[20]. Interestingly, the site bound by MITF comprises an 
extended palindromic E box sequence (5’-TCACGTGA) 
characteristic of the MITF binding sites (Figure 5G 
and S4A). In silico analysis revealed that this promoter 
sequence is highly conserved during evolution (Figure 
S4B). In conclusion, our results indicate that MITF 
controls SIRT1 expression at the transcriptional level and 
point out to a melanocyte-specific regulation of SIRT1.
SIRT1 mediates MITF effect
We next sought to determine the importance of 
SIRT1 in the senescence phenotype mediated by MITF 
suppression. SIRT1 forced expression (Figure 6A), led to 
an increased SIRT1 activity (Figure 6B), and prevented 
SA-βGal staining mediated by MITF-suppression in 
melanoma cells (Figure 6C). In addition, the increase in 
H3K9 acetylation and in the level of γH2AX observed in 
response to MITF-suppression was dramatically reduced 
upon SIRT1 forced expression (Figure 6D). Likewise, 
SIRT1 forced expression strongly reduced NF-κB 
activation (Figure 6E) and production of CCL2 (Figure 
6F) mediated by MITF knock-down. Finally, SIRT1 forced 
expression partially rescued the ability of MITF-deleted 
501mel cells to form colonies (Figure 6G). In conclusion, 
our results indicate that SIRT1 acts downstream of MITF 
in the regulation of melanoma cell proliferation. 
Figure 5: MITF regulates SIRT1 expression at the transcriptional level. (A) qRT-PCR analysis of the genes indicated on the 
figure in 501mel melanoma cells transfected with control, MITF or SIRT1 siRNA for 96 hrs. Relative changes in mRNA level compared 
with control (Log2) is shown. (B) qRT-PCR analysis of the genes indicated on the figure in 501mel melanoma cells transfected with control 
or MITF siRNA for 96 hrs. Relative mRNA level is shown. (C) Western blot analysis of melanoma cells transfected with control or two 
different MITF siRNA. (D) 501mel cells were exposed to hypoxia (1% O2) for the time indicated and lysates were analysed by western 
blot. (E) Western blot analysis of 501mel cells transduced with control or MITF encoding adenovirus. (F) 501mel cells were exposed 
to forskolin (20 µM) for the time indicated and lysates were analysed by western blot. (G) UCSC view of 3HA-tagged wild-type MITF 
occupancy at the SIRT1 locus in 501mel cells. The sequence of the E box and promoter (blue) are shown.
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SIRT1 mediates PLX4032 resistance
MITF has been involved in PLX4032 resistance. 
We therefore asked whether SIRT1, a downstream 
MITF target, might contribute to this resistance. In 
BRAFV600E-expressing 501mel cells, PLX4032 inhibited 
ERK2 activation as shown by the decreased ERK2 
phosphorylation, and induced cell death illustrated by the 
Figure 6: SIRT1 prevents the senescence phenotypes 
caused by MITF suppression. (A) Western blot analysis of 
cells transfected with a vector encoding FLAG-tagged SIRT1. 
(B) In vitro deacetylation assay in cells transfected with an 
empty vector (EV) or a vector encoding FLAG-tagged SIRT1. 
Activity is expressed as the percentage of activity with respect 
to the control (EV). AFU, Arbitrary fluorescence units. Error bar 
represents the SEM of triplicate experiments. (C) 501mel cells 
were transfected with control (siC) or MITF siRNA and/or an 
empty vector or a vector encoding FLAG-tagged SIRT1 for 96 
hrs. Cells were stained for SA-βGal activity (x10 magnification). 
Results are expressed as the mean ± the standard deviation of 
three experiments of SA-βGal positive cells. (D) Same as © 
but analysed by western blot. (E) Control or MITF-suppressed 
501mel cells were transfected with κB-Luc reporter plasmid 
plus an empty vector or a vector encoding FLAG-tagged SIRT1 
for 96 hrs. NF-kB luciferase activity is expressed relative to 
control cells. (F) Same as (C) but examined for expression of the 
CCL2 mRNA. (G) Colony formation of 501mel cells transfected 
with control, or MITF siRNA ± a vector encoding FLAG-tagged 
SIRT1 was assessed after 14 days. Representative images of 
colonies formed are shown.
Figure 8: SIRT1 inhibition impairs melanoma cell 
growth and resistance to PLX4032. (A) Western Blot 
analysis of PLX4032 sensitive (WM9S) or resistant (WM9R) 
WM9 melanoma cells exposed to PLX4032 5µM. (B) Number 
of WM9S and WM9R cells exposed to PLX4032 5µM and 
10µM for 96 hrs. (C) In vitro deacetylation assay in WM9S and 
WM9R cells exposed to PLX4032 5µM for 96 hrs. (D) WM9S 
and WM9R melanoma cells were left in basal condition or 
exposed to SIRT1 inhibitors, EX-527 (34 µM) and sirtinol (163 
µM) in presence or absence of PLX4032 5µM. Colonies were 
stained with crystal violet after 14 days. Representative images 
of colonies formed are shown. (E) Same as (D). Colonies were 
destained and the relative absorbance, which reflects the number 
of colonies was measured on a spectrophotometer. 
Figure 7: SIRT1 contributes to PLX4032 resistance. 
(A) 501mel melanoma cells control or transfected with a 
FLAG-tagged SIRT1 were exposed to PLX4032 (5µM) for 96 
hrs. Lysates were analyzed by western blotting. (B) 501mel 
melanoma cells control or transfected with a FLAG-tagged 
SIRT1 were exposed to PLX4032 (5µM or 10µM) for 48 hrs. 
Relative cell viability was expressed as a percentage (%) of the 
control cells (EV).
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cleavage of PARP1 (Figure 7A) and the decrease in cell 
viability (Figure 7B). After 96 hrs, the decrease in cell 
viability (Figure 7B) was associated with a reduction in 
SIRT1 level (Figure 7A). However, it should be noted that 
short time treatment with PLX4032 (24 hrs), efficiently 
inhibited ERK2 phosphorylation but had no effect on 
SIRT1 level (Figure 8A) and was not associated with cell 
growth arrest or death (not shown). Moreover, forced 
expression of SIRT1 prevented the cleavage of PARP1 
and rendered 501mel cells resistant to PLX4032 effect. 
Therefore, SIRT1 attenuates PLX4032 effect. 
We next thought to determine the activity of 
SIRT1 in BRAFV600E-mutated WM9 melanoma cells 
sensitive (WM9S) to PLX4032 and in their resistant 
counterpart (WM9R). As expected, WM9S exposed to 
PLX4032 displayed almost no ERK phosphorylation 
and no change in levels of total ERK, which reflected an 
inhibition of ERK activity (Figure 8A). In WM9R, ERK2 
phosphorylation remained elevated all along the time 
course. Consequently, PLX4032 dramatically reduced 
the number of cells (Figure 8B) and colonies (Figures 
8D-E) in the WM9S but not in the WM9R. Interestingly, 
WM9R exhibited an enhanced SIRT1 level and activity 
compared with WM9S (Figures 8A and 8C). Moreover, 
SIRT1 expression and activity was strongly reduced after 
exposure to PLX4032 in WM9S, but not in WM9R, where 
SIRT1 expression and activity remained high (Figures 8A 
and 8C). We conclude that high SIRT1 correlates with 
PLX4032 resistance.
Using pharmacological approaches, we investigated 
whether inhibition of SIRT1 may improve the response 
to PLX4032. The SIRT1-specific inhibitor EX-527 [21] 
or sirtinol, a synthetic small-molecule inhibitor of SIRT1 
and SIRT2 [22] suppressed proliferation as illustrated by 
a decreased number of cells and colony formed in WM9S 
and in WM9R (Figures 8D-E). Whereas PLX4032 had 
no effect in the resistant WM9R cells, a strong reduction 
in colony formation ability was achieved by PLX4032 in 
WM9S. However, PLX4032, and the SIRT1 inhibitors, 
had a synergistic effect leading to an almost complete 
inhibition of cell proliferation in both WM9S and WM9R. 
Moreover, these data indicated that SIRT1 inhibition 
rescued the sensitivity to PLX4032 of WM9R.
In conclusion, these results support the idea that 
SIRT1 plays a role in the resistance to PLX4032 of 
melanoma cells and that a combination therapy consisting 
of PLX4032 and SIRT1 inhibitors represents a valuable 
therapeutic option.
DISCUSSION
This study was designed to investigate the role 
of SIRT1 in melanoma cells. Here, we demonstrate 
that SIRT1 suppression by genetic or pharmacological 
approaches triggers a cessation of cell proliferation and 
senescence-like phenotype. Indeed, in addition to the 
β-galactosidase activity at pH6, which although imperfect 
is the most widely used marker of senescence, SIRT1-
suppressed melanoma cells display changes in morphology 
characterized by an increase in cell size and granularity, 
and an increase in the level of cell cycle inhibitors. 
These effects that are observed in several melanoma 
cell types or cells freshly isolated from human biopsy of 
different genetic background, link SIRT1 to melanoma 
cell proliferation. We also find that senescence in SIRT1-
suppressed cells is accompanied by a decrease expression 
in HDMX. In line with this, HDMX knock-down 
promoted senescence in human prostate adenocarcinoma 
cells [23]. 
Our findings reveal for the first time a lineage-
specific control of SIRT1 expression. The M-isoform 
of MITF is specifically expressed in melanocytes [24] 
and nearly all melanoma cells express MITF [25]. Our 
observations indicate that MITF regulates expression 
of SIRT1 at the transcriptional level, as evidenced by a 
change in SIRT1 mRNA and protein level and ChIP-seq 
data showing binding of MITF to the promoter of SIRT1. 
Analysis of the SIRT1 promoter reveals the presence of 
a MITF-binding site composed of 5’-TCACGTGA-3’. 
This sequence matches perfectly the MITF consensus 
site previously reported, with a T in 5’ and an A in 3’ 
[26]. Moreover, we found a paralleled expression of 
MITF and SIRT1 in response to stimuli involved in 
melanocyte differentiation (cAMP-elevating agents) and 
in melanomagenesis (hypoxia). It would be interesting to 
determine if SIRT1 indeed mediates the effect of MITF in 
these contexts. 
Some melanoma cell lines displays very low MITF 
level. As MITF has been shown both in vitro and in vivo 
to be critical to melanoma cell proliferation/survival [4, 
27], A375 or 1205Lu cells with very low level of MITF 
have likely adapted to the lost of MITF. 
One explanation for the lack of correlation between 
MITF and SIRT1 in such cells is that, SIRT1 expression 
is regulated by other transcription factors, which activities 
might be influenced by the genetic background of the 
cells, previously reported to control SIRT1 expression 
[28]. Another explanation is that SIRT1 expression might 
be regulated by transcription factors homologous to MITF, 
such as TFE3 or TFEB. Both hypotheses remain to be 
investigated. 
Whereas, SIRT1 null mice were embryonic lethal 
[29], Sirt1+/- heterozygous mice show signs of premature 
aging, such as graying coat. In this mouse model, hair 
graying has been shown to result from defective self-
maintenance of melanocyte stem-cells within the niche 
[30]. Hair graying is also observed in the Mivit/vit mouse 
model [31], which expresses the D222N substitution in 
the transcription factor MITF and causes a progressive 
loss of the melanocytes [24]. Whether SIRT1 expression 
is decreased in the melanocyte stem cells in vivo, 
and contributes to the melanocyte lost, remains to be 
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determined. Nevertheless, the data from both our in vitro 
results and from in vivo models support the idea that 
SIRT1 activity is critically required for melanocyte cell 
proliferation.
The regulation of SIRT1 by MITF suggests the 
existence of other tissue-restricted mechanisms of SIRT1 
regulation. These tissue-specific regulations would 
contribute to SIRT1 activity in a tissue-specific manner 
and might explain the apparent discrepancies regarding 
SIRT1 function in different cell types. 
SIRT1 has been shown to control the MAPK/ERK 
signaling pathway [32] and vice versa [33-35]. In our 
model system, neither forced expression of SIRT1 (Figure 
7A) nor short-term SIRT1-suppression affect the level 
of phospho-ERK (data not shown). These observations 
indicate that SIRT1 does not regulate the MAPK/ERK 
signaling pathway at least in the melanoma cell line 
used in this study. Noteworthy, SIRT1 level decreases in 
PLX4032-treated melanoma cells after 96 hours (Figure 
7A). However, a shorter treatment with PLX4032 (Figure 
8A, lane 2) efficiently inhibits ERK2 phosphorylation, but 
it has no effect on SIRT1 level. In this later condition, we 
also observe no growth arrest or cell death (not shown).
However, longer exposure to PLX4032 (Figure 
7A and 8B left part), reduces the number of cells and is 
associated with a decrease in SIRT1 level. In aggregates, 
our results suggest that SIRT1 level may be reduced 
as a result of growth arrest/cell death mediated by the 
inhibitors of the BRAF/MEK/ERK pathway. This is in 
agreement with previous reports showing a reduction in 
SIRT1 level ensuing caspase activation [33, 35]. 
Our results show that SIRT1 over-expression 
rescued melanoma proliferation arrest mediated by 
MITF knock-down, thereby indicating that SIRT1 is an 
effector of MITF-induced cellular proliferation. Therefore, 
deregulation of SIRT1 might play an important role in 
melanoma pathogenesis. Recently, MITF was reported 
to contribute to PLX4032 resistance [36]. Moreover, 
MITF through regulation of PGC1α, has been shown to 
mediate a metabolic rewiring that limits the efficacy of 
BRAF inhibitors [37, 38]. Importantly, SIRT1 regulates 
PGC1αacetylation which is thought to be crucial for its 
activity [39, 40]. These data suggest that MITF might 
coordinate the expression of different proteins involved 
in oxidative metabolism in melanoma cells. Moreover, 
PGC1α has been shown to limit the efficacy of PLX4032 
[37] and to mediate the resistance to chemotherapy drug 
[41]. We find an increased activity of SIRT1 in PLX4032 
resistant BRAFV600E-mutated melanoma cells compared 
with their sensitive counterpart, thereby linking SIRT1 
to drug resistance and poor prognosis in melanoma. In 
that context, we demonstrate that inhibition of SIRT1 
with genetic or pharmacological approaches additively 
enhances the efficacy of PLX4032 of melanoma cells 
but more importantly that it rescues the sensitivity to 
PLX4032 of the resistant BRAFV600E-mutated melanoma 
cells. 
The findings gathered in this study not only 
contribute to better understand the role of MITF in 
melanoma cells but also provide strong support that 
targeting SIRT1 is a valuable clinical option to treat 
malignant melanoma. 
MATERIALS AND METHODS
Cell cultures, transfection and luciferase activity
The human melanoma cells were grown in DMEM 
supplemented with 7% FBS at 37°C in a humidified 
atmosphere containing 5%CO2. 501mel, 1205Lu, A375, 
WM9 and SBCL2 are wild type for p53 and SKmel28 
(L145R) and M14 (G266E) are p53 mutated. SBCL2 and 
WM9 cells were obtained from M. Herlyn. Fresh sterile 
tissues were obtained from surgical waste from patients 
diagnosed for metastatic melanoma at the Nice CHU 
hospital and treated as reported [27]. Informed consent 
was obtained from the patients.
For siRNA transfection, a single pulse of 50nM of 
siRNA was administrated to the cells at 50% confluency 
by transfection with 5µl lipofectamineTM RNAiMAX in 
opti-MEM medium (Invitrogen, San Diego, CA, USA). 
Control (siC) and MITF (siMi) siRNAs were previously 
described [42]. SIRT1 siRNA was from Sigma. For 
luciferase assay, cells were transiently transfected as 
previously described [5] using the lipofectamine reagent 
(Invitrogen).
Senescence-Associated β-Galactosidase Assay
The senescence β-galactosidase staining kit from 
Cell Signaling Technology (Beverly, MA, USA) was 
used to histochemically detect β-galactosidase activity at 
pH6. The percentage of means and standard deviations 
were derived from counting 100 cells in duplicate plates 
after 96 hrs. Cells were also labeled with 20 nM C12FDG 
(Sigma) for 1 h. The cells were detached from the plate 
and analyzed by flow cytometry (MACSQuant® Miltenyi 
Biotech) using the fluorescein channel. Arbitrary units 
(median channel fluorescence) are reported.
Western blot assays
Briefly, cell lysates (30µg) were separated by SDS-
PAGE, transferred on to a PVDF membrane and then 
exposed to the appropriate antibodies, anti-MITF and 
anti- H3K9acetyl were from Abcam, anti-ERK2, anti-
CDK2, and anti-p27KIP1 antibodies were from Santa Cruz 
Biotechnology, anti-SIRT1 and anti-phospho-ERK1/2 
(Thr202/Tyr204) were from Cell Signaling Technology 
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Inc. (Beverly, MA). Horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse antibodies were from Dakopatts 
(Glostrup, Denmark). Proteins were visualized with the 
ECL system (Amersham). The western blots shown are 
representative of at least 3 independent experiments.
Proliferation curves
Cells were seeded in 12-well dishes (10x103 cells) 
and 48 hrs post-transfection, cells were trypsinized from 
days 2 to 6, counted in triplicate by haemocytometer to 
assess cell proliferation. The experiment was performed 
at least three times.
Flow cytometry
Cells were stained with propidium iodide (40μg/ml) 
containing ribonuclease A (10μg/ml) and were analyzed 
using a fluorescence activated cell sorter (MACSQuant® 
Analyzer) and MACSQuantifyTM software.
Immunofluorescence and confocal microscopy
Immunofluorescence experiments were carried out 
as previously described [15] and examined with the 20X 
objective using Zeiss Axiophot microscope equipped with 
epifluorescence illumination.
mRNA preparation, Real-time/quantitative PCR
mRNA isolation was performed with Trizol 
(Invitrogen), according to standard procedure. QRT-
PCR was carried out with SYBR® Green I (Eurogentec, 
Seraing, Belgium) and Multiscribe Reverse Transcriptase 
(Applied Biosystems) and monitored by an ABI Prism 
7900 Sequence Detection System (Applied Biosystems, 
Foster City, CA). Detection of RPL14 gene was used 
to normalize the results. Primer sequences for each 
cDNA were designed using either Primer Express 
Software (Applied Biosystems) or qPrimer depot (http://
primerdepot.nci.nih.gov) and are available upon request.
Colony-forming assays 
Cells (2×103) were seeded in 12-well dishes or on a 
layer of the nonadhesive 1% polyHEMA surface. The cells 
were then placed in a 37°C, 5% CO2 incubator. Colonies of 
cells were allowed to grow for 14 days. The colonies were 
stained with 0.04% crystal violet/2% ethanol in PBS for 
30 min. Photographs of the stained colonies were taken. 
The colony formation assay was performed in duplicate.
SIRT1 Activity
SIRT1 activity was measured by using the SIRT1 
Assay Kit (Sigma). In this assay, SIRT1 activity is 
assessed by the degree of deacetylation of a substrate 
which represents a peptide containing amino acids 379-
382 of human p53 (Arg-His-Lys-Lys[Ac]). SIRT1 activity 
is directly proportional to the degree of deacetylation of 
Lys-382. Nuclear cell lysates (quantity) were incubated 
with peptide substrate (25 μM) in a phosphate-buffered 
saline solution at 37°C for 45 minutes. The reaction was 
stopped with the addition of 2 mM nicotinamide and a 
developing solution that binds to the deacetylated lysine 
to form a fluorophore. Following 10 minutes incubation at 
37°C, fluorescence was read in a plate-reading fluorometer 
at an excitation wavelength of 360 nm and an emission 
wavelength of 450 nm. In each assay, human recombinant 
SIRT1 enzyme (1 Unit per well), a SIRT1 activator, and 
suramin sodium (5 mM), a SIRT1 inhibitor were utilized 
as positive and negative controls in each set of reactions. A 
standard curve was constructed using deactylated substrate 
(0-10 μM). Data for endogenous SIRT1 activation were 
normalized to cellular protein concentration measured via 
BCA-assay. 
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